CATL Shares Fall as Hungary Plant Faces Safety Halt 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Add as a preferred source on Google
West Lafayette, Ind., Feb. 22, 2018 -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Feb. 26th, at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering Phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR-T therapy into the clinic in 2018, where it will be studied in pediatric osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
